靶向治疗联合化疗在脑肿瘤患者中的应用效果
|
摘要
目的探讨靶向治疗联合化疗在脑肿瘤患者中的临床治疗效果。方法选取2016年10月～2018年10月我院收治的50例脑肿瘤患者为研究对象,随机将其分为观察组(n=25)和对照组(n=25),观察组给予靶向治疗联合化疗治疗,对照组仅给予化疗治疗。对比两组患者的治疗总有效率、生活质量改善情况以及不良反应发生情况。结果观察组的临床治疗有效率为72.0%,明显高于对照组的44.0%(P<0.05);观察组的生活质量改善率为76.0%,明显高于对照组的48.0%(P<0.05);观察组的口腔炎、恶心呕吐、脱发、贫血、白细胞减少、血小板减少、肝功能异常的发生率明显明显低于对照组(P<0.05)。结论脑肿瘤患者采用靶向治疗联合化疗的治疗方式具有显著的疗效,而且可以降低不良反应发生率,安全性高,值得大力推广。
Objective To investigate the clinical therapeutic effect of targeted therapy combined with chemotherapy in patients with brain tumors. Methods Fifty patients with brain tumors admitted in our hospital from October 2016 to October 2018 were enrolled in the study. They were randomly divided into observation group(n=25) and control group(n=25). The observation group was given targeted therapy combined with chemotherapy, and the control group was given only chemotherapy. The total effective rate of treatment, quality of life improvement and adverse reactions were compared between the two groups. Results The clinical effective rate of the observation group was 72.0%, which was significantly higher than that of the control group(44.0%)(P<0.05). The improvement rate of quality of life in the observation group was 76.0%, which was significantly higher than that of the control group(48.0%)(P<0.05). The incidence of stomatitis, nausea and vomiting, alopecia, anemia, leukopenia, thrombocytopenia, and abnormal liver function in the observation group was significantly lower than that in the control group(P<0.05). Conclusion Targeted therapy combined with chemotherapy in the treatment of brain tumor patients has significant curative effect, and can reduce the incidence of adverse reactions, with high safety, which is worthy of promotion.
Objective To investigate the clinical therapeutic effect of targeted therapy combined with chemotherapy in patients with brain tumors. Methods Fifty patients with brain tumors admitted in our hospital from October 2016 to October 2018 were enrolled in the study. They were randomly divided into observation group(n=25) and control group(n=25). The observation group was given targeted therapy combined with chemotherapy, and the control group was given only chemotherapy. The total effective rate of treatment, quality of life improvement and adverse reactions were compared between the two groups. Results The clinical effective rate of the observation group was 72.0%, which was significantly higher than that of the control group(44.0%)(P<0.05). The improvement rate of quality of life in the observation group was 76.0%, which was significantly higher than that of the control group(48.0%)(P<0.05). The incidence of stomatitis, nausea and vomiting, alopecia, anemia, leukopenia, thrombocytopenia, and abnormal liver function in the observation group was significantly lower than that in the control group(P<0.05). Conclusion Targeted therapy combined with chemotherapy in the treatment of brain tumor patients has significant curative effect, and can reduce the incidence of adverse reactions, with high safety, which is worthy of promotion.
引文
[1]陈宓,贾霖,韩建军,等.肺癌脑转移患者应用靶向治疗联合放化疗同步治疗的疗效及安全性研究[J].现代生物医学进展,2016,16(35):6913-6915.
[2]贾敬好,王静,王巍,等.Ⅲ级和Ⅳ级脑胶质瘤术后放疗联合替莫唑胺化疗的疗效观察[J].河北医药,2017,39(3):337-341.
[3]吴鹏昌,苏永永,谢江涛,等.脑胶质瘤术后放疗联合替莫唑胺与颈动脉灌注尼莫司汀同步化疗疗效对比分析[J].陕西医学杂志,2016,45(9):1133-1135.
[4]苏书娟.放疗联合培美曲塞或多西他赛治疗非小细胞肺癌靶向治疗失败合并脑转移患者的疗效对比研究[J].中国全科医学,2017,20(z1):66-68.
[5]龚星,陈国庆.脑放疗联合靶向治疗与同步放、化疗治疗非小细胞肺癌脑转移对疾病控制率及中位生存期的影响分析[J].医学理论与实践,2018,31(9):71-72.
[6]邹乐乐.榄香烯单药或联合放化疗在脑恶性肿瘤中的效果分析[J].中国实用神经疾病杂志,2016,19(6):118-119.
[7]王洋,方健,聂鋆,等.非小细胞肺癌脑转移放疗时机的选择及疗效预后分析[J].中国肺癌杂志,2016,19(8):508-514.
[8]李自强.健脑化瘤汤联合VD化疗方案治疗脑部恶性肿瘤临床研究[J].新中医,2016,48(11):148-150.
[9]Ning Z,Chen D,Liu A,et al.Efficacy of chemotherapy combined with targeted arterial infusion of verapamil in patients with advanced gastric cancer[J].Cell Biochemistry and Biophysics,2014,68(1):195-200.
[10]员建中.全脑放疗联合替莫唑胺化疗治疗脑转移肿瘤的疗效及安全性分析[J].中外医疗,2016,35(28):115-117.
[11]魏刚刚.靶向治疗联合化疗在脑肿瘤患者中的临床疗效研究[J].中国保健营养,2019,29(3):90.
[12]Li W,Wang Y,Zhao L,et al.Efficacy of retroNectin-activated cytokine-induced killer cell therapy in metastatic brain tumor patients[J].Oncology Research and Treatment,2015,38(4):160-165.
[13]崔毓辉,李树勇,李海燕.全脑放疗联合化疗在非小细胞肺癌脑转移中的应用[J].中国肿瘤临床与康复,2016,23(11):1313-1315.
[14]倪峰,何晓军,陆美芹,等.替莫唑胺联合放疗对脑肿瘤疗效的临床研究[J].实用临床医药杂志,2017,21(11):166-167.
[15]涂勤.超选介入化疗联合放疗对脑胶质细胞瘤术后抑制残留细胞的疗效研究[J].中国当代医药,2017,24(22):39-41.
[2]贾敬好,王静,王巍,等.Ⅲ级和Ⅳ级脑胶质瘤术后放疗联合替莫唑胺化疗的疗效观察[J].河北医药,2017,39(3):337-341.
[3]吴鹏昌,苏永永,谢江涛,等.脑胶质瘤术后放疗联合替莫唑胺与颈动脉灌注尼莫司汀同步化疗疗效对比分析[J].陕西医学杂志,2016,45(9):1133-1135.
[4]苏书娟.放疗联合培美曲塞或多西他赛治疗非小细胞肺癌靶向治疗失败合并脑转移患者的疗效对比研究[J].中国全科医学,2017,20(z1):66-68.
[5]龚星,陈国庆.脑放疗联合靶向治疗与同步放、化疗治疗非小细胞肺癌脑转移对疾病控制率及中位生存期的影响分析[J].医学理论与实践,2018,31(9):71-72.
[6]邹乐乐.榄香烯单药或联合放化疗在脑恶性肿瘤中的效果分析[J].中国实用神经疾病杂志,2016,19(6):118-119.
[7]王洋,方健,聂鋆,等.非小细胞肺癌脑转移放疗时机的选择及疗效预后分析[J].中国肺癌杂志,2016,19(8):508-514.
[8]李自强.健脑化瘤汤联合VD化疗方案治疗脑部恶性肿瘤临床研究[J].新中医,2016,48(11):148-150.
[9]Ning Z,Chen D,Liu A,et al.Efficacy of chemotherapy combined with targeted arterial infusion of verapamil in patients with advanced gastric cancer[J].Cell Biochemistry and Biophysics,2014,68(1):195-200.
[10]员建中.全脑放疗联合替莫唑胺化疗治疗脑转移肿瘤的疗效及安全性分析[J].中外医疗,2016,35(28):115-117.
[11]魏刚刚.靶向治疗联合化疗在脑肿瘤患者中的临床疗效研究[J].中国保健营养,2019,29(3):90.
[12]Li W,Wang Y,Zhao L,et al.Efficacy of retroNectin-activated cytokine-induced killer cell therapy in metastatic brain tumor patients[J].Oncology Research and Treatment,2015,38(4):160-165.
[13]崔毓辉,李树勇,李海燕.全脑放疗联合化疗在非小细胞肺癌脑转移中的应用[J].中国肿瘤临床与康复,2016,23(11):1313-1315.
[14]倪峰,何晓军,陆美芹,等.替莫唑胺联合放疗对脑肿瘤疗效的临床研究[J].实用临床医药杂志,2017,21(11):166-167.
[15]涂勤.超选介入化疗联合放疗对脑胶质细胞瘤术后抑制残留细胞的疗效研究[J].中国当代医药,2017,24(22):39-41.